Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : EBS crawled time : 11:00 save search
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
Published: 2023-10-19 (Crawled : 11:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: -0.87%
H: 0.87%
C: -3.06%
conference financial results
Emergent BioSolutions Partners with Emmitt Smith to Launch Ready to Rescue Campaign to Help Save Lives Amidst Rising Opioid Epidemic
Published: 2023-10-16 (Crawled : 11:00) - prnewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: 0.79%
H: 0.72%
C: -2.76%
opioid save ready
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
Published: 2023-10-02 (Crawled : 11:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.3%
H: 0.0%
C: 0.0%
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: 0.0%
H: 0.15%
C: -7.06%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.77%
H: 0.0%
C: 0.0%
LQDA M | $13.31 -3.62% -3.76% 830K
|
Health Technology
|
| O: 0.0%
H: 0.16%
C: -1.74%
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
Published: 2023-08-08 (Crawled : 11:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: -0.27%
H: 0.0%
C: -2.44%
business financial
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
Published: 2023-07-25 (Crawled : 11:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: -1.09%
H: 0.97%
C: -3.31%
conference financial results
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
Published: 2023-05-11 (Crawled : 11:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: -0.74%
H: 1.4%
C: -2.05%
meeting
Kamada Awarded $22 Million Extension of Canadian Supply Tender
Published: 2022-10-19 (Crawled : 11:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: -1.07%
H: 1.14%
C: -4.04%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -1.52%
H: 3.31%
C: -0.44%
extension
Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022
Published: 2022-10-18 (Crawled : 11:00) - biospace.com/
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: 2.29%
H: 1.17%
C: -4.91%
conference financial results
Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate
Published: 2022-09-06 (Crawled : 11:00) - biospace.com/
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: -0.48%
H: 0.0%
C: -2.58%
candidate vaccine virus study phase 1
Emergent BioSolutions to Participate in Investor Conferences - Aug 10, 2022
Published: 2022-08-10 (Crawled : 11:00) - biospace.com/
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: 1.35%
H: 2.43%
C: 1.55%
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: 2.56%
H: 0.39%
C: 0.07%
Emergent BioSolutions to Participate in Investor Conferences
Published: 2022-08-10 (Crawled : 11:00) - globenewswire.com
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: 1.35%
H: 2.43%
C: 1.55%
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: 2.56%
H: 0.39%
C: 0.07%
Kamada Announces $11.4 Million International VARIZIG® Procurement Agreement
Published: 2022-07-06 (Crawled : 11:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: 5.33%
H: 1.3%
C: -0.82%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: 0.0%
H: 3.52%
C: 2.86%
varizig agreement international
Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate
Published: 2022-06-24 (Crawled : 11:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: 6.55%
H: 0.91%
C: -0.27%
av7909 fda candidate vaccine application license
Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases
Published: 2022-06-21 (Crawled : 11:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: 5.29%
H: 0.0%
C: 0.0%
lancet publication chikungunya disease phase 2
Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
Published: 2022-05-16 (Crawled : 11:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: -2.17%
H: 2.19%
C: -0.73%
CMRX | $0.8844 -5.14% -5.42% 430K
|
Health Technology
|
| O: -53.48%
H: 2.58%
C: -14.43%
tembexa smallpox antiviral
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDT
Published: 2022-05-12 (Crawled : 11:00) - biospace.com/
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: -6.49%
H: 0.0%
C: 0.0%
Emergent BioSolutions to Release First Quarter 2022 Financial Results and Conduct Conference Call on April 28, 2022
Published: 2022-04-08 (Crawled : 11:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: 0.4%
H: 2.26%
C: -1.93%
conference results
Emergent BioSolutions to Release Third Quarter 2021 Financial Results and Conduct a Conference Call on November 4, 2021
Published: 2021-10-18 (Crawled : 11:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: -3.26%
H: 1.6%
C: 0.52%
financial results results merge conference
Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19
Published: 2021-08-25 (Crawled : 11:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: 0.0%
H: 2.91%
C: 2.5%
covid treatment phase 3 trial merge
Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021
Published: 2021-07-15 (Crawled : 11:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: -0.94%
H: 4.82%
C: 4.12%
financial results results merge conference